March 12, 2020 / 11:55 AM / 25 days ago

BRIEF-Cosmo Pharmaceuticals: FDA Extends NDA Review Period For BYFAVO(TM)

March 12 (Reuters) - COSMO PHARMACEUTICALS NV:

* FDA HAS EXTENDED REVIEW PERIOD FOR NEW DRUG APPLICATION (NDA) FOR BYFAVO(TM) (REMIMAZOLAM) BY UP TO 90 DAYS

* EXTENSION IN ORDER TO COMPLETE ITS REVIEW OF ADDITIONAL DATA SUBMITTED IN JANUARY AND FEBRUARY 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below